Literature DB >> 8359904

Virulence of enterohemorrhagic Escherichia coli O91:H21 clinical isolates in an orally infected mouse model.

S W Lindgren1, A R Melton, A D O'Brien.   

Abstract

Escherichia coli K-12 strains producing high levels of Shiga-like toxin type II (SLT-II) but not SLT-I were previously shown to be virulent in an orally infected, streptomycin-treated mouse model. In this investigation, we tested the virulence of several SLT-II-producing enterohemorrhagic E. coli (EHEC) isolates from patients with hemorrhagic colitis or hemolytic uremic syndrome. All of the strains tested were able to colonize the mouse intestine. However, only two strains were consistently virulent for mice: O91:H21 strain B2F1 (Strr), which was previously shown to carry two copies of slt-II-related toxins, and O91:H21 strain H414-36/89 (Strr), which was found in this study to contain three genes from the slt-II group. The oral 50% lethal doses of strains B2F1 (Strr) and H414-36/89 (Strr) when fed to streptomycin-treated mice were less than 10 bacteria. Histological sections from moribund mice fed the O91:H21 strains demonstrated extensive renal tubular necrosis; however, hematological results were not consistent with a diagnosis of hemolytic uremic syndrome. The central role of SLT in the virulence of the O91:H21 EHEC strains was supported by the finding that streptomycin-treated mice preinoculated with monoclonal antibody specific for SLT-II survived oral challenge with either B2F1 (Strr) or H414-36/89 (Strr). The basis for the variation in virulence among the SLT-II-producing EHEC strains tested was not determined. However, a correlation between the capacity of an EHEC strain to grow in small intestinal mucus and lethality in the streptomycin-treated mice was observed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8359904      PMCID: PMC281084          DOI: 10.1128/iai.61.9.3832-3842.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  54 in total

1.  Red-blood-cell fragmentation in microangiopathic haemolytic anaemia: in-vitro studies.

Authors:  B S Bull; M L Rubenberg; J V Dacie; M C Brain
Journal:  Lancet       Date:  1967-11-25       Impact factor: 79.321

2.  Intestinal epithelial cell surface membrane glycoprotein synthesis. I. An indicator of cellular differentiation.

Authors:  M M Weiser
Journal:  J Biol Chem       Date:  1973-04-10       Impact factor: 5.157

3.  Hemolytic-uremic syndrome associated with verotoxin-producing Escherichia coli.

Authors:  S Ratnam; S March; C Ojah; D Hillman; R Ozere
Journal:  Can Med Assoc J       Date:  1985-07-01       Impact factor: 8.262

4.  Rapid and specific detection of verotoxin genes in Escherichia coli by the polymerase chain reaction.

Authors:  D R Pollard; W M Johnson; H Lior; S D Tyler; K R Rozee
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

5.  Sporadic cases of hemorrhagic colitis associated with Escherichia coli O157:H7.

Authors:  R S Remis; K L MacDonald; L W Riley; N D Puhr; J G Wells; B R Davis; P A Blake; M L Cohen
Journal:  Ann Intern Med       Date:  1984-11       Impact factor: 25.391

6.  Shiga-like toxin-converting phages from Escherichia coli strains that cause hemorrhagic colitis or infantile diarrhea.

Authors:  A D O'Brien; J W Newland; S F Miller; R K Holmes; H W Smith; S B Formal
Journal:  Science       Date:  1984-11-09       Impact factor: 47.728

7.  Isolation and characterization of Shigella shigae cytotoxin.

Authors:  S Olsnes; K Eiklid
Journal:  J Biol Chem       Date:  1980-01-10       Impact factor: 5.157

8.  Hemorrhagic colitis associated with a rare Escherichia coli serotype.

Authors:  L W Riley; R S Remis; S D Helgerson; H B McGee; J G Wells; B R Davis; R J Hebert; E S Olcott; L M Johnson; N T Hargrett; P A Blake; M L Cohen
Journal:  N Engl J Med       Date:  1983-03-24       Impact factor: 91.245

9.  Quantitative microtiter cytotoxicity assay for Shigella toxin.

Authors:  M K Gentry; J M Dalrymple
Journal:  J Clin Microbiol       Date:  1980-09       Impact factor: 5.948

10.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli.

Authors:  M A Karmali; M Petric; C Lim; P C Fleming; G S Arbus; H Lior
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

View more
  63 in total

1.  Role of rpoS in acid resistance and fecal shedding of Escherichia coli O157:H7.

Authors:  S B Price; C M Cheng; C W Kaspar; J C Wright; F J DeGraves; T A Penfound; M P Castanie-Cornet; J W Foster
Journal:  Appl Environ Microbiol       Date:  2000-02       Impact factor: 4.792

2.  Association of virulence genotype with phylogenetic background in comparison to different seropathotypes of Shiga toxin-producing Escherichia coli isolates.

Authors:  Jean Pierre Girardeau; Alessandra Dalmasso; Yolande Bertin; Christian Ducrot; Séverine Bord; Valérie Livrelli; Christine Vernozy-Rozand; Christine Martin
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

3.  Shiga toxin 2 subtypes of enterohemorrhagic E. coli O157:H- E32511 analyzed by RT-qPCR and top-down proteomics using MALDI-TOF-TOF-MS.

Authors:  Clifton K Fagerquist; William J Zaragoza
Journal:  J Am Soc Mass Spectrom       Date:  2015-02-10       Impact factor: 3.109

4.  The common ovine Shiga toxin 2-containing Escherichia coli serotypes and human isolates of the same serotypes possess a Stx2d toxin type.

Authors:  V Ramachandran; M A Hornitzky; K A Bettelheim; M J Walker; S P Djordjevic
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

5.  Subtyping method for Escherichia coli shiga toxin (verocytotoxin) 2 variants and correlations to clinical manifestations.

Authors:  Søren Persson; Katharina E P Olsen; Steen Ethelberg; Flemming Scheutz
Journal:  J Clin Microbiol       Date:  2007-04-19       Impact factor: 5.948

6.  Use of the flagellar H7 gene as a target in multiplex PCR assays and improved specificity in identification of enterohemorrhagic Escherichia coli strains.

Authors:  V P Gannon; S D'Souza; T Graham; R K King; K Rahn; S Read
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

7.  Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice.

Authors:  Jun Fujii; Mariko Naito; Takashi Yutsudo; Sohkichi Matsumoto; Daniel P Heatherly; Takeshi Yamada; Hideyuki Kobayashi; Shin-Ichi Yoshida; Tom Obrig
Journal:  Clin Vaccine Immunol       Date:  2012-10-03

8.  Direct evidence of neuron impairment by oral infection with verotoxin-producing Escherichia coli O157:H- in mitomycin-treated mice.

Authors:  J Fujii; T Kita; S Yoshida; T Takeda; H Kobayashi; N Tanaka; K Ohsato; Y Mizuguchi
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

9.  Non-O157:H7 Stx2-producing Escherichia coli strains associated with sporadic cases of hemolytic-uremic syndrome in adults.

Authors:  R Bonnet; B Souweine; G Gauthier; C Rich; V Livrelli; J Sirot; B Joly; C Forestier
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

10.  The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coli differ when measured by Vero cell cytotoxicity but not by mouse lethality.

Authors:  S W Lindgren; J E Samuel; C K Schmitt; A D O'Brien
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.